TherapeuticsMD IncChange company Symbol lookupSelect an option...TXMD TherapeuticsMD IncZNOG Zion Oil and Gas IncPM Philip Morris International IncAFRM Affirm Holdings IncRMI RiverNorth Opportunistic Municipal Income Fund, Inc.NVDA NVIDIA CorpLBAI Lakeland Bancorp IncBREA Brera Holdings PLCGVYB Golden Valley BankDHC Diversified Healthcare TrustGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
TherapeuticsMD, Inc. is a healthcare company. The Company is focused on developing and commercializing products exclusively for women. It is engaged in conducting business by out-licensing its products and collecting royalties, after granting a license to commercialize the Company's IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and its possessions and territories and assigning the Company’s exclusive license to commercialize ANNOVERA in the United States and its possessions and territories to Mayne Pharma. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive vaginal system (CVS)). ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone (SA) and ethinyl estradiol (EE). Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia.
|
|
|
|
| |
TXMD's position in the Pharmaceuticals industry
| Industry Peers | AMRX | |
|---|---|---|
Summary | ||
| Company Profile | TherapeuticsMD, Inc. is a healthcare company. The Company is focused on developing and commercializing products exclusively for women. It is engaged in conducting business by out-licensing its... | Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company specializes in developing, manufacturing, marketing and distributing generic, injectables, biosimilars and branded specialty... Go to AMRX summary |
| 52-Week Change | VS. INDUSTRY | -23.72% |
| Market Cap | VS. INDUSTRY | $775.9M |
| Beta | VS. INDUSTRY | 1.3 |
| Dividend Yield | VS. INDUSTRY | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | -- |
| Data as of | ||
Fundamentals | ||
| Total Revenue (TTM) | VS. INDUSTRY | $2.3B |
| Profit Margin | VS. INDUSTRY | -11.37% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 8.29% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.